Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | -30.86M | -27.73M | -17.91M | -10.17M |
EBITDA | -251.27M | -252.39M | -256.94M | -345.84M | -287.03M |
Net Income | -266.76M | -283.25M | -269.48M | -355.93M | -285.31M |
Balance Sheet | |||||
Total Assets | 501.02M | 565.30M | 822.72M | 1.13B | 730.30M |
Cash, Cash Equivalents and Short-Term Investments | 152.50M | 205.19M | 434.01M | 746.88M | 412.00M |
Total Debt | 94.20M | 104.10M | 108.25M | 110.94M | 71.91M |
Total Liabilities | 250.52M | 277.79M | 323.40M | 400.90M | 1.15B |
Stockholders Equity | 250.50M | 287.51M | 499.31M | 728.50M | -421.18M |
Cash Flow | |||||
Free Cash Flow | -256.58M | -273.61M | -310.93M | -280.92M | -161.85M |
Operating Cash Flow | -223.15M | -253.58M | -290.05M | -251.05M | -137.98M |
Investing Cash Flow | 17.45M | 172.01M | 210.56M | -245.80M | -252.56M |
Financing Cash Flow | 199.75M | 31.65M | 4.91M | 631.75M | 435.69M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
65 Neutral | $818.39M | ― | 222.83% | ― | 29.88% | 35.11% | |
60 Neutral | HK$17.01B | 5.40 | -7.44% | 3.26% | 11.55% | -28.15% | |
54 Neutral | $641.40M | ― | -49.91% | ― | -14.16% | 25.88% | |
51 Neutral | $656.06M | ― | -28.73% | ― | 189.31% | 51.03% | |
42 Neutral | $409.11M | ― | -30.10% | ― | ― | -343.40% | |
33 Underperform | $1.04B | ― | -71.44% | ― | ― | 19.94% |
Sana Biotechnology announced promising results from its hypoimmune platform (HIP) that show potential in overcoming allogeneic and autoimmune rejection, notably in type 1 diabetes. The company’s approach, which addresses a significant limitation in transplant medicine, could transform treatment options for various diseases, enhancing its industry positioning and offering new hope for patients with unmet medical needs.